All Type of News
The healthcare industry practically declared the end of MERS
While there has been no additional MERS patient occurred for 22 days, the healthcare industry practically declared the end of MERS.
The Korean Medical Association(President Moo-jin Choo), the Korean Hospital Associat...
A domestic biosimilar taking an unstoppable run in the global market
The Celltrion’s rheumatoid arthritis treatment, ‘Remsima,’ has continued to accelerate in the global market. The number of exports from the early year to June has already exceeded the one of the last whole year.
Rems...
Multinational pharmaceutical companies’ reasonable reorganization
Gigantic multinational pharmaceuticals have shown the instinct like a chameleon.
Although the instinct has always been found in history of the pharmaceutical industry, its method has never been same.
The keyword reg...
The 2nd domestic DPP-4 inhibitor attracted attention with high expectation of global commercialization
The DPP-4(dipepitdyl peptidase-4) diabetes new drug developed by Dong-A ST for the second time as a domestic company, Evogliptin, is expected to become a role model of the global commercialization.
This is because th...
The 3-way competition of Pfizer, Lilly and Astellas in the oral RA treatment
As Pfizer, Lilly and Astellas entered the domestic oral rheumatoid arthritis treatment market, the 3-way competition has been formed.
Astellas Korea was recently approved for a clinical trial on its rheumatoid arthri...
About 10 mid-sized pharmaceutical companies are working on IPO
Domestic mid-sized pharmaceutical companies have attracted attention via IPO.
According to the industry concerned, at most 10 foreign and domestic companies, such as the largest Korean transfusion agent company affil...
24 people from Korea Pharmaceutical Information Center and IMS were suspected for leaking personal information
On suspicion of illegal collection and sales of patient treatment and prescription information, 24 people from institutions, such as the Korea Pharmaceutical Information Center and IMB Health Korea, were prosecuted.
...
What are so ‘innovative’ about ‘NOAC’ applauded by physicians?
Foreign and domestic guidelines, recently, have aggressively recommended NOAC(New-Oral Anti-Coagulant) as an anticoagulant to prevent stoke and systemic embolism of atrial fibrillation patients.
Thus, NOAC has been a...
The secret of a foreign company recording over KRW 70 billion only with 4 products is ‘specialization’
There is a foreign pharmaceutical company recording KRW 70 billion sales in the domestic market only with 4 product approvals.
The leading role of the drama is ‘Gilead Sciences Korea’ acquiring an approval for the ph...
Will the key leader of non-benefit products, filler, continuously grow? The answer will be shown at KRW 100 billion
Will the filler market, which has been in the limelight as a non-benefit medication, become a limitless gold mine for the pharmaceutical industry?
The filler market became a market worth of KRW 90 billion last year, ...
